Gut Microbiome Diversity in Adults With Inflammatory and Immune-Mediated Skin Diseases (GUMIDIC)
Studio Sulla diversità Del Microbiota Intestinale Umano in Pazienti Con Patologie Infiammatorie Cutanee
This study will examine whether the gut bacteria of adults with inflammatory or immune-mediated skin diseases differ from those of healthy adults. It will include people with atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, or bullous pemphigoid, as well as healthy controls.
Participants will provide a stool sample and complete a short food diary. The study team will analyze the bacteria in the samples and compare the results between the disease groups and healthy controls. Participants with a skin disease will be asked to provide a second stool sample and complete follow-up assessments about six months later; healthy controls will provide one sample. The study will also examine whether changes in gut bacteria are related to skin disease severity, diet, and other collected health information.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Gianluca Nazzaro, MD
- Telefonnummer: +39 0255035200
- E-Mail: gianluca.nazzaro@policlinico.mi.it
Studienorte
-
-
-
Milan, Italien, 20122
- Rekrutierung
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Kontakt:
- Gianluca Nazzaro, MD
- Telefonnummer: +39 0255035200
- E-Mail: gianluca.nazzaro@policlinico.mi.it
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Adults aged 18 years or older with one of eight specialist-confirmed inflammatory or immune-mediated skin diseases, plus healthy adult controls without those diseases. Participants are recruited through the Dermatology service at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy.
Beschreibung
Inclusion Criteria:
- Age 18 years or older.
- Able and willing to provide informed consent.
- For patient groups: specialist-confirmed diagnosis of atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, or bullous pemphigoid.
- For healthy controls: no diagnosis of the skin diseases studied.
Exclusion Criteria:
- Unable to provide informed consent or complete the study procedures.
- Systemic antibiotic treatment within 8 weeks before recruitment or during follow-up.
- Previous intestinal surgery.
- Inflammatory bowel disease, constipation, or diarrhea.
- Long-term alcohol use.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: CASE_CONTROL
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
|---|
|
Atopic Dermatitis
Adults aged 18 years or older with dermatologist-confirmed atopic dermatitis. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Psoriasis
Adults aged 18 years or older with dermatologist-confirmed psoriasis. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Hidradenitis Suppurativa
Adults aged 18 years or older with dermatologist-confirmed hidradenitis suppurativa. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Vitiligo
Adults aged 18 years or older with dermatologist-confirmed vitiligo. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Acne
Adults aged 18 years or older with dermatologist-confirmed acne. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Pemphigus
Adults aged 18 years or older with dermatologist-confirmed pemphigus. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Bullous Pemphigoid
Adults aged 18 years or older with dermatologist-confirmed bullous pemphigoid. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Healthy Controls
Adults aged 18 years or older who do not have the skin diseases studied. Participants provide one stool sample and complete study assessments at baseline. |
|
Alopecia Areata
dults aged 18 years or older with dermatologist-confirmed alopecia areata. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Relative abundance of Bifidobacteriaceae in stool
Zeitfenster: Baseline (T1)
|
Compare the relative abundance of the bacterial family Bifidobacteriaceae in stool between the combined group of adults with the eight skin diseases studied and healthy controls. Relative abundance is the number of sequences assigned to Bifidobacteriaceae divided by the total number of bacterial sequences. |
Baseline (T1)
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Relative abundance of Enterobacteriaceae in stool in the combined patient group
Zeitfenster: Baseline (T1)
|
Compare the relative abundance of Enterobacteriaceae in stool between the combined group of adults with the eight skin diseases studied and healthy controls. |
Baseline (T1)
|
|
Relative abundance of Bifidobacteriaceae by skin-disease group
Zeitfenster: Baseline (T1)
|
Compare stool Bifidobacteriaceae relative abundance between each disease group-atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, and bullous pemphigoid-and healthy controls. |
Baseline (T1)
|
|
Relative abundance of Enterobacteriaceae by skin-disease group
Zeitfenster: Baseline (T1)
|
Compare stool Enterobacteriaceae relative abundance between each of the eight disease groups and healthy controls. |
Baseline (T1)
|
|
Change in stool Bifidobacteriaceae and Enterobacteriaceae over time
Zeitfenster: Baseline (T1) to 6 months (T2)
|
Assess within-person changes in the relative abundance of Bifidobacteriaceae and Enterobacteriaceae between T1 and T2 in participants with skin disease. |
Baseline (T1) to 6 months (T2)
|
|
Associations between gut bacteria and disease-related measures
Zeitfenster: Baseline (T1) and 6 months (T2)
|
Explore associations between Bifidobacteriaceae and Enterobacteriaceae relative abundance and disease activity scores, psychological impact scores, available routine laboratory markers, dietary intake, and anthropometric measures, as specified in the protocol. |
Baseline (T1) and 6 months (T2)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Genetische Krankheiten, angeboren
- Autoimmunerkrankungen
- Erkrankungen des Immunsystems
- Infektionen
- Überempfindlichkeit, sofort
- Überempfindlichkeit
- Hautkrankheiten, papulosquamös
- Hautkrankheiten
- Alopezie
- Hypotrichose
- Haarkrankheiten
- Bakterielle Infektionen
- Bakterielle Infektionen und Mykosen
- Erkrankungen der Schweißdrüsen
- Hautkrankheiten, bakteriell
- Hautkrankheiten, ansteckend
- Eiterung
- Hautkrankheiten, genetisch
- Hautkrankheiten, Ekzem
- Akneartige Eruptionen
- Erkrankungen der Talgdrüsen
- Hautkrankheiten, Vesikulobullöse
- Dermatitis
- Hidradenitis
- Angeborene, erbliche und neonatale Krankheiten und Anomalien
- Haut- und Bindegewebserkrankungen
- Alopecia Areata
- Hidradenitis suppurativa
- Schuppenflechte
- Dermatitis, atopisch
- Akne vulgaris
- Pemphigus
- Pemphigoid, Bullös
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- GUMIDIC
- 6708 (Andere Kennung: Comitato Etico Territoriale Lombardia 3)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .